H.C. Wainwright raised the firm’s price target on Sangamo (SGMO) to $10 from $5 and keeps a Buy rating on the shares. The firm says the accelerated clinical development plan in Fabry disease may support an application filing in the first half of 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks